Related Experiment Video
Updated: Dec 12, 2025
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical
Milena Tocut1,2, Yehuda Shoenfeld2,3,4, Gisele Zandman-Goddard1,2
1Department of Internal Medicine C, Wolfson Medical Center , Holon, Israel.
Introduction:
Systemic lupus erythematosus (SLE) is a chronic disease that is potentially fatal. There is no cure for SLE and the medications used are associated with toxic side effects. In the era of revolutionary emerging novel biologic agents, the design and investigation of targeted therapy for these patients is necessary. Novel therapies under investigation in phase II-III clinical trials showed promising results. Therapies can target various pathways involved in SLE including cytokines, signal transduction inhibitors, B-cell depletion and interference with co-stimulation. Of interest is the proof of concept of sequential therapy.
Areas Covered:
We performed an extensive literature search via PubMed, Medline, Elsevier Science and Springer Link databases between the years 2014-2020 using the following terms: SLE, novel treatments. We have reviewed 232 articles and selected those articles that (i) focus on phase II-III emerging therapies and (ii) offer new findings from existing therapies, which reveal breakthrough concepts in SLE treatment.
Expert Opinion:
It is still difficult to crack the puzzle of a successful SLE treatment approach. New strategies with potential may encompass the targeting of more than one protein. Another way forward is to identify each SLE patient and personalize therapy by clinical manifestations, disease activity, serology and activated protein.
Insights
Novel biologic agents offer promising treatments for systemic lupus erythematosus (SLE), a chronic autoimmune disease. Personalized and targeted therapies, potentially involving multiple pathways, are key to future SLE management.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a chronic, potentially fatal autoimmune disease with no cure.
- Current SLE treatments have toxic side effects, necessitating novel therapeutic approaches.
- Emerging biologic agents and targeted therapies show promise in clinical trials.
Purpose of the Study:
- To review emerging phase II-III therapies for SLE.
- To identify breakthrough concepts in SLE treatment from recent findings.
- To explore novel therapeutic strategies for managing SLE.
Main Methods:
- Extensive literature search of PubMed, Medline, Elsevier Science, and Springer Link (2014-2020).
- Keywords used: SLE, novel treatments.
- Selection criteria: focus on phase II-III emerging therapies and new findings offering breakthrough concepts.
Main Results:
- Novel therapies target various SLE pathways, including cytokines, signal transduction, B-cell depletion, and co-stimulation interference.
- Sequential therapy presents a potential treatment strategy.
- Emerging treatments in phase II-III trials demonstrate promising results.
Conclusions:
- Personalized therapy based on individual patient profiles (clinical, serological, activity) is crucial for SLE management.
- Targeting multiple proteins simultaneously may offer a more effective treatment strategy.
- Developing successful SLE treatment approaches remains challenging but evolving.
Related Concept Videos
01:28Preclinical Development: Overview
01:21EPS and iPS Cells in Disease Research
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:22iPS Cell Differentiation